ReviewCell stem cell2019
Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids.
Review in Cell stem cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- OrgLine: A versatile pipeline for organoid morphometry using detector-guided prompts.Cell reports methods · 2026Article
- Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.Nature reviews. Neurology · 2026Review
- Patient-derived tumor organoids for new drug development: promises and challenges.Investigational new drugs · 2026Review
- LIG1 overexpression enhances DNA repair and immune escape leading to poor prognosis in osteosarcoma.European journal of medical research · 2025Article
- VHL Gene Restoration Supports RCC Reprogramming to iPSCs but Does Not Ensure Line Stability.Cancers · 2025Article
- Iteration of Tumor Organoids in Drug Development: Simplification and Integration.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Quantum machine learning-based electrokinetic mining for the identification of nanoparticles and exosomes with minimal training data.Bioactive materials · 2025Article
- Bridging the gap between tumor and disease: Innovating cancer and glioma models.The Journal of experimental medicine · 2025Review
- Human stem cell models to unravel brain cancer.BMC cancer · 2024Review
- Inhibition of lung tumorigenesis by transient reprogramming in cancer cells.Cell death & disease · 2024Article
- Non-small cell lung cancer organoids: Advances and challenges in current applications.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications.Signal transduction and targeted therapy · 2024Review
- Stromal thrombospondin 1 suppresses angiogenesis in oral submucous fibrosis.International journal of oral science · 2024Article
- Three-DimensionalInternational journal of biological sciences · 2024Review
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Preclinical Models of Visceral Sarcomas.Biomolecules · 2023Review
- In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced.Journal of personalized medicine · 2023Review
- ActivatedInternational journal of oncology · 2023Article
- Rewired mNature communications · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cell lines and animal models have provided the foundation of cancer research for many years. However, human pluripotent stem cells (hPSCs) and organoids are increasingly enabling insights into tumor development, progression, and treatment. Here, we review recent studies using hPSCs to elucidate the reciprocal roles played by genetic alterations and cell identity in cancer formation. We also review studies using human organoids as models that recapitulate both intra- and inter-tumoral heterogeneity to gain new insights into tumorigenesis and treatment responses. Finally, we highlight potential opportunities for cancer research using hPSC-derived organoids and genome editing in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.